Literature DB >> 30859503

Capsule Commentary on Anthenelli et al., Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial.

Derek D Satre1,2, Kelly C Young-Wolff3,4.   

Abstract

Year:  2019        PMID： 30859503      PMCID： PMC6544767          DOI： 10.1007/s11606-019-04909-8

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  5 in total

1.  Screening for suicide risk in adolescents, adults, and older adults in primary care: U.S. Preventive Services Task Force recommendation statement.

Authors:  Michael L LeFevre
Journal:  Ann Intern Med       Date:  2014-05-20       Impact factor: 25.391

2.  Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial.

Authors:  Robert M Anthenelli; Michael Gaffney; Neal L Benowitz; Robert West; Thomas McRae; Cristina Russ; David Lawrence; Lisa St Aubin; Alok Krishen; A Eden Evins
Journal:  J Gen Intern Med       Date:  2019-03-07       Impact factor: 5.128

3.  Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions.

Authors:  Bridget F Grant; Deborah S Hasin; S Patricia Chou; Frederick S Stinson; Deborah A Dawson
Journal:  Arch Gen Psychiatry       Date:  2004-11

Review 4.  Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

Authors:  Kate Cahill; Sarah Stevens; Rafael Perera; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

5.  Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

Authors:  Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins
Journal:  Lancet       Date:  2016-04-22       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.